President and Chief Executive Officer
Paul Chaney is president and CEO of PanOptica, Inc., a start-up, venture-backed private biopharma company, with a mission to develop innovative ophthalmic therapeutics. Prior to co-founding PanOptica, Paul was executive vice president of OSI Pharmaceuticals and president of (OSI) Eyetech, OSI’s eyecare subsidiary. He joined Eyetech Pharmaceuticals as chief operating officer in 2003. Paul has nearly 30 years of experience in the pharmaceutical industry, including a variety of senior management positions at Pharmacia Corporation. At Pharmacia, Paul served as vice president of the Global Ophthalmology Business and as vice president of Global Pharmaceutical Ophthalmology. He began his career as a sales representative for The Upjohn Company in 1980. Paul earned a dual degree in Biological Sciences and English from the University of Delaware.
Martin Wax, M.D.
Chief Medical Officer and Executive Vice-President
Martin B. Wax, M.D., is chief medical officer and executive vice president of R&D at PanOptica, Inc., a private biotechnology company specializing in ophthalmic pharmaceuticals. He previously served as vice president of R&D and head of discovery research and preclinical sciences at Alcon Laboratories, where he was responsible for the creation and early development of the Alcon pharmaceutical portfolio. Dr. Wax received his medical degree from the University of Southern California in Los Angeles. He completed his residency in Ophthalmology at Wills Eye Hospital in Pennsylvania, and post-doctoral fellowships in molecular pharmacology and glaucoma at the University of Pennsylvania School of Medicine. He currently holds an appointment as a Professor of Ophthalmology and Visual Sciences at the University of Texas Southwestern Medical School in Dallas, and has been selected as one of the “Best Doctors in America” by his peers. An internationally recognized scientific expert in the field of glaucoma, Dr. Wax has co-authored more than 200 publications and serves on several scientific advisory committees and editorial boards.
Please click here to download Dr. Wax's CV
Executive Director of Finance and Controller
Lori Forrest is the executive director of finance and controller at PanOptica, Inc. She has over 20 years of accounting experience in the pharmaceutical and consumer products industries. Her responsibilities have included financial reporting (including SEC reporting requirements and compliance with the Sarbanes-Oxley Act of 2002), budgets and forecasts, and human resource and information technology functions. Most recently, Lori was the Controller at Helsinn Therapeutics, Inc. (previously Sapphire Therapeutics, Inc.), where she played a key role in the due-diligence, merger and post-acquisition integration activities when Sapphire was purchased in January 2009. From 1997-2005, Lori worked at Vivus, Inc. in roles of increasing responsibility in both operations and corporate finance. She began her career at Carter-Wallace, Inc. after graduating from Cook College, Rutgers University with a Bachelor of Science degree in Business Economics. Lori is a certified public accountant.
David P. Bingaman, DVM, Ph.D.
Senior Director of Clinical Development
As senior director of clinical development at PanOptica, Inc., David Bingham, DVM, Ph.D., is responsible for managing PanOptica’s Retina programs, including PAN-90806, the company’s lead therapeutic candidate. David previously spent 13 years at Alcon Laboratories in Ft. Worth, Texas, where he established Ocular Angiogenesis and Diabetic Retinopathy programs, directed various aspects within Retina Development, and received the Alcon Technical Excellence Award in 2006. Dr. Bingaman earned his veterinary medical degree from Washington State University and completed an internship and residency in veterinary ophthalmology at Purdue University. He conducted his doctoral thesis in pathologic ocular angiogenesis and diabetic retinopathy in a combined program at Purdue University/Indiana University. Dr. Bingaman is a board-certified veterinary ophthalmologist and Diplomate of the American College of Veterinary Ophthalmologists.
Executive Director of Clinical Operations
As executive director of clinical operations for PanOptica, Inc., Kristine Curtiss brings 20 years of experience in the pharmaceutical, biotechnology, and medical device industries. Previously, Kristine managed all phases of global clinical trials on strategic programs in neurology and oncology at Hoffman La-Roche, Inc. Her work there led to the approval of Tasmar® (tolcapone) and Xeloda® (capecitabine) in the United States and in Europe. Kristine also served as Executive Director of Clinical Research at Eyetech Pharmaceuticals, where she was responsible for implementing and directing the clinical program leading to the U.S. and European approvals of Macugen® (pegaptanib sodium) for neovascular age-related macular degeneration. Previously, she was director of global ophthalmology programs at Opko Health and Oraya Therapeutics, Inc. Kristine holds a Bachelor of Science degree in Chemistry from the University of Delaware.